Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130819 · ClinicalTrials.gov registry record · Phase 2
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
A Phase 2 study of HIV Infections and Opiate Dependence, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00130819 is a Phase 2 study of HIV Infections and Opiate Dependence that has completed, run by Johns Hopkins University. The registered enrollment target is 120 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00130819, a Phase 2 study of HIV Infections and Opiate Dependence, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effectiveness of two approaches to treating HIV-infected patients who are addicted to opioid drugs (e.g., heroin) in an inner-city HIV clinic. The two approaches are: * Case management and referral - participants are managed by a case manager and referred to a specialized drug treatment center where they receive counseling and medications for opioid-dependence (e.g., methadone or buprenorphine); or * Clinic-based treatment - participants receive counseling and treatment with buprenorphine at the HIV clinic.
Conditions Studied
Interventions
- BEHAVIORAL Clinic-based substance abuse treatment with buprenorphine
- BEHAVIORAL Case management and referred substance abuse treatment
Study Locations (1)
Maryland
- Johns Hopkins HIV Clinic - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130819
The ClinicalTrials.gov registry entry for NCT00130819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Clinic-based substance abuse treatment with buprenorphine is the first listed.
NCT00130819 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00130819 about?
NCT00130819 is a clinical study titled "Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants". The purpose of this study is to compare the effectiveness of two approaches to treating HIV-infected patients who are addicted to opioid drugs (e.g., heroin) in an inner-city HIV clinic. The two approaches are: * Case management and referral - participants are managed by a case manager and referred...
What is the current status of trial NCT00130819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2005-11. Estimated completion is 2009-04.
What conditions does trial NCT00130819 study?
This clinical trial studies the following conditions: HIV Infections, Opiate Dependence, HIV Seropositivity.
What interventions are being tested in trial NCT00130819?
The interventions under investigation include: Clinic-based substance abuse treatment with buprenorphine (BEHAVIORAL), Case management and referred substance abuse treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00130819?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00130819 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.